J.Jpn. Surg. Soc.. 118(6): 622-627, 2017

---

Feature topic

ANTI-HER2 TARGETED THERAPY AND HER2-POSITIVE BREAST CANCER SURGERY

According to Japanese Breast Cancer Registry data, among more than 250,000 patients from 2004 through 2011, HER2-positive primary cases comprised 12.3-15.5％ of the total. The 2004 Annual Prognosis Analysis Report revealed that triple-negative breast cancer had the poorest prognosis and was an HER2-positive subtype. In the Japanese guidelines, postoperative adjuvant chemotherapy combined with trastuzumab for HER2-positive breast cancer is recommended. The same long-term effects have been shown for standard chemotherapy if applied either in the preoperative or postoperative setting. Therefore, for HER2-positive breast cancer, preoperative anti-HER2 therapy is recommended. A pathological complete response (pCR) to preoperative therapy has a prognostic impact, especially in HER2-positive breast cancer. Preoperative chemotherapy aimed at achieving pCR combined with trastuzumab and pertuzumab is the currently recommended anti-HER2 therapy.

---

---

To read the PDF file you will need Adobe Reader installed on your computer.